🔹 EPS: -$2.91 (Est. -$2.68) 🔴
🔹 Revenue: $966M (Est. $942.8M) 🟢
🔹 R&D Expenses: $1.12B (Est. $1.16B) 🟢
🔹 Product Sales: $923M (vs. $2.8B YoY)
FY25 Guidance :
🔹 Revenue: $1.5B–$2.5B (Est. $2.43B) 🔴
🔹 R&D Expenses: ~$4.1B
🔹 SG&A Expenses: ~$1.1B
🔹 Cash Position (Year-End): ~$6B
Key Business Updates:
COVID-19 Vaccine (Spikevax®):
🔹 Q4 Sales: $923M (U.S.: $244M; International: $679M)
🔹 Full-Year Sales: $3.1B
🔹 Regulatory filing for next-gen COVID-19 vaccine (mRNA-1283); FDA decision expected by May 31, 2025.
RSV Vaccine (mRESVIA®):
🔹 Q4 Sales: $15M; Full-Year Sales: $25M.
🔹 Approved in multiple regions, including the U.S., EU, and Canada.
Flu/COVID Combination Vaccine:
🔹 Phase 3 immunogenicity data shared; regulatory filing submitted.
Pipeline Progress:
🔹 Submitted three Biologics License Applications (BLA) in Q4, including RSV and COVID combination vaccines.
🔹 Anticipates up to 10 product approvals by 2027.
Management Commentary:
Stéphane Bancel, CEO:
🔹 "We exceeded our cost reduction goals in 2024 and advanced key late-stage pipeline programs. With a strong focus on operational efficiency, we expect significant product approvals starting this year, driving long-term growth."
Additional Notes:
🔹 Cost Efficiency: Achieved a 27% reduction in operating expenses compared to 2023.
🔹 Strategic Focus: Transitioning to seasonal commercial markets for respiratory vaccines while expanding R&D in oncology and rare diseases.